Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.
Giacomo Tini MelatoGiuliano TocciAllegra BattistoniMatteo SarocchiCamilla PietrantoniDomitilla RussoBeatrice MusumeciCarmine SavoiaMassimo VolpePaolo SpallarossaPublished in: Current heart failure reports (2023)
Not adequately controlled AH before or during anticancer treatments and/or development of AH during or after completion of such therapies have detrimental effects on the clinical course of oncologic patients, particularly if HMOD is present. As overlooking CV health can jeopardize the success of anticancer treatments, the goal for clinicians caring for the oncologic patient should include the treatment of AH and HMOD.
Keyphrases
- arterial hypertension
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- public health
- blood pressure
- chronic kidney disease
- rectal cancer
- radical prostatectomy
- mental health
- robot assisted
- peritoneal dialysis
- palliative care
- prostate cancer
- prognostic factors
- oxidative stress
- health information
- climate change